Strategic partnerships Multiply Labs has ongoing and expanding collaborations with Thermo Fisher Scientific, Legend Biotech, Retro Biosciences, and Portal Biotechnologies, signaling strong partnership opportunities with large pharma, cell therapy developers, and bioprocess players for automation integrations.

Expanded funding momentum Recent funding of 41.3M and a multi-round financing history indicate capital availability and a growth trajectory, suggesting timing is favorable for customers to adopt scalable robotic manufacturing solutions and for channel partners to align on joint go-to-market efforts.

Scale ready capabilities With a revenue range of 100M to 250M and a specialization in automating cell therapy manufacturing at scale, Multiply Labs is positioned to address end-to-end automation needs for biotech and pharma clients seeking to increase throughput and reduce manual bottlenecks.

Industry breadth Active engagements across immune-oncology and gene/modality spaces, plus collaborations with bioreactor and cell engineering platforms, create cross-sell and integration opportunities with equipment manufacturers, software vendors, and contract development/manufacturing organizations.

Growth through integration Existing tech stack and recent integrations indicate an emphasis on interoperable automation. This suggests sales opportunities around modular robotic ecosystems, API-enabled workflows, and partnerships that extend automation from manufacturing cells to broader bioprocess platforms.